Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.
Microdose GLP OneEvidence Edition · Updated July 20, 2026

Safety hub

Microdose GLP-1 safety

Class effects, compounded-product uncertainty, and the practical dosing risks that matter most.

Microdose GLP-1 safety spans the medication's class effects, the extra uncertainty of compounded products, and practical risks like dosing errors and concentration changes. Compounded products are not FDA approved and are not reviewed for safety, effectiveness, or quality before marketing.

What the evidence shows

  • GLP-1 class side effects (nausea, vomiting, diarrhea, constipation) are well described.
  • Serious warnings on the approved labels apply to those products and their indicated uses.

What the evidence does not show

  • That a lower or compounded dose is automatically safer or free of these effects.
  • That compounded products carry the same quality assurances as approved ones — they are not FDA reviewed.
Dosing errorsUnits, mg, and concentration.Units vs milligramsWhy they are not the same.GI side effectsWhat to expect and red flags.Verify a pharmacyConfirm who is compounding.
Clinical safety pages are reviewer-gated. Specific safety pages index only after pharmacist/medical review; several are in that queue.

Frequently asked questions

Is a lower dose safer?

Not automatically. Lower doses often cause fewer GI effects, but 'safer' is not proven, and compounded products carry quality uncertainty regardless of dose.

Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.